Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by Sarb99on Jan 31, 2021 7:58pm
251 Views
Post# 32433240

More collection sites equal more revenue & higher SP

More collection sites equal more revenue & higher SP

Medivolve share price should start moving up with more testing sites coming online. Medivolve should have 87 collection sites generating revenue compared to 54 last week. Percentage-wise, this is about a 62% increase. All this means Over a 60% increase in revenue. Any increase in the revenue usually is reflected in the share price. 

 

Also, anyone shorting MEDV should be more careful shorting or even start covering any short. As with increased revenue, investors will start taking notice. 87 collection sites with the lowest announced numbers of 75 tests per site can bring in big money for Medivolve. 

 

Here is a little example 87x75=6525 tests per day and 195,750 tests per month, and with an average of $95 per test, can generate USD 18,596,250 per month. Converting this to Canadian is about 18,596,250x1.28= $23,803,200 CAD per month. Collection sites with 87 testing sites can generate $285,638,400 per year. Keep in mind for this probably take 3-4 weeks for people to know about these sites. So, we add 3-4 weeks to reach 75 tests per site, average numbers. 

 

Once they complete the second phase. The third phase is to add another 70 collection sites https://medivolve.ca/investor-presentation/. So progress does not start here. 

 

Also, with all this money, Medivolve can start investing in other technologies like they did last week in Marvel Diagnostics Inc https://medivolve.ca/medivolve-announces-investment-into-marvel-diagnostics-and-its-non-invasive-exhaled-breath-diagnostic-technology/

<< Previous
Bullboard Posts
Next >>